

# Programmable m<sup>6</sup>A modification of cellular RNA with a Cas13-directed methyltransferase

Christopher Wilson, Peter J. Chen, Zhuang Miao, David R. Liu

## SUPPLEMENTARY INFORMATION

Supplementary Figure 1. *In vitro* kinetics of m<sup>6</sup>A methyltransferases

Supplementary Figure 2. Structural analysis of METTL3:METTL14 and PbuCas13b

Supplementary Figure 3. Orthogonal assay for on-target RNA methylation by TRM editors in *E. coli*

Supplementary Figure 4. MeRIP-seq of *Cluc*–*Socs2* targeted by TRM editors

Supplementary Figure 5. Effect of dCas13 binding on transcript stability and translation

Supplementary Figure 6. Validation of targeted *Actb* methylation by TRM editors

Supplementary Figure 7. Cellular protein expression of TRM editors

Supplementary Figure 8. Validation of targeted *Gapdh* methylation by TRM editors

Supplementary Figure 9. Validation of targeted *Foxm1* methylation by TRM editors

Supplementary Figure 10. Validation of targeted *Sox2* methylation by TRM editors

Supplementary Figure 11. Orthogonal validation of TRM with MazF-qPCR

Supplementary Figure 12. MeRIP-seq of *Actb* mRNA targeted by TRM editors

Supplementary Figure 13. TRM editing window on *Actb*

Supplementary Figure 14. Sequence preferences of TRM editors

Supplementary Figure 15. Effect of TRM editors on cellular m<sup>6</sup>A content

Supplementary Figure 16. Off-target methylation by TRM editors

Supplementary Figure 17. Endogenous methylation levels of TRM editor off-targets

Supplementary Figure 18. Effects of TRM editors on transcriptome-wide distribution of m<sup>6</sup>A

Supplementary Figure 19. Effects of TRM editors on cellular transcriptome abundances

Supplementary Figure 20. Comparison of TRM editors with M3M14–dCas9 editors

Supplementary Figure 21. *Gapdh* RNA expression changes from TRM editing

Supplementary Table 1. RNA oligonucleotides used for *in vitro* kinetics assays

Supplementary Table 2. Sequences of Cas13 guide RNA spacers used in this work

Supplementary Table 3. Sequences of Cas9 guide RNA spacers and PAMmers used in this work

Supplementary Table 4. Sequences of guide RNA-quenching DNA oligonucleotides used for RNA purification

Supplementary Table 5. Sequences of RT-qPCR primers used for MeRIP-RT-qPCR assays


Supplementary Table 6. Sequences of primers used for semi-quantitative PCR in alternative splicing assays

Supplementary Sequences 1. Amino acid sequences of TRM editor constructs


Supplementary Sequences 2. Sequences of exogenous reporter transcripts targeted by TRM editor constructs

Supplementary References.

Construct	$K_m$ (nM)	$V_{max}$ ( $h^{-1}$ )
METTL3	> 900	$8.6 \pm 1.11$
METTL3:METTL14	$18 \pm 1.76$	$24 \pm 0.50$




**Supplementary Figure 1. *In vitro* kinetics of m<sup>6</sup>A methyltransferases.** Michaelis-Menten kinetics of purified METTL3 and METTL3:METTL14 activity on a ssRNA substrate.  $k_{obs}$  = observed catalytic rate. Values reflect the mean  $\pm$  s.e.m. of  $n=3$  independent reactions.




**Supplementary Figure 2. Structural analysis of METTL3:METTL14 and PbuCas13b.** (a) Crystal structure of the METTL3<sup>369-570</sup>:METTL14<sup>117-402</sup> heterodimer (PDB 5IL1)<sup>1</sup>. (b) Co-crystal structure of *Prevotella buccae* Cas13b (PbuCas13b, brown) bound to the CRISPR RNA hairpin of a guide RNA (PDB 6DTD, grey and blue)<sup>2</sup>. The N-terminus (red) and C-terminus (blue) are shown for each protein.







**Supplementary Figure 3. Orthogonal assay for on-target RNA methylation by TRM editors in *E. coli*.** Fluorescence measurements of indicated quantities of RNA captured and stained with fluorescent anti-m<sup>6</sup>A antibodies to assay relative levels of m<sup>6</sup>A modification. Columns 1-2: m<sup>6</sup>A-modified control RNA and unmodified control RNA were commercially synthesized and served as positive and negative controls. Columns 3-5: synthetic transcript was targeted with indicated TRM editors within *E. coli*, purified from cells, selectively enriched, then quantified for m<sup>6</sup>A abundance. dCas13-dM3 represents a methyltransferase-inactive dCas13-M3<sup>D395</sup> control. a.u. = fluorescence in arbitrary units.




**Supplementary Figure 4. MeRIP-seq of *Cluc*–*Socs2* targeted by TRM editors.** *Cluc*–*Socs2* read coverage of input (grey) and m<sup>6</sup>A-immunoprecipitated (red, m<sup>6</sup>A IP) RNA from MeRIP-seq of transfected HEK293T cells. TRM constructs **(a)** dCas13–M3 and **(b)** dCas13–M3M14 targeted the *Socs2* 3' UTR under the following conditions: active editor with a target guide RNA, inactive editor with a target guide RNA, and active editor with a non-target guide RNA. Inactive TRM editors contain a methyltransferase-inactivating D395A mutation within M3. The target guide RNA (purple) and targeted m<sup>6</sup>A sites are shown. Cpm = counts per million reads. MeRIP-seq analysis was performed with n=3 independent biological replicates.




**Supplementary Figure 5. Effect of dCas13 binding on transcript stability and translation. (a)** Schematic of dCas13 targeting assay. Nucleus- (dCas13nes) or cytoplasm-localized dCas13 (dCas13nls), guide RNAs (purple), and a dual luciferase plasmid were transfected in HEK293T cells prior to measurement of luciferase RNA abundance and luminescence. *Cypridina* luciferase (*Cluc*, green) reporter transcripts were targeted by dCas13, while *Gaussia* luciferase (*Gluc*, orange) served as a dosing control for normalization. **(b)** dCas13 targeting *Cluc* with guide RNAs tiled across the *Cluc* coding sequence (CDS). **(c)** dCas13 targeting the 3' UTRs of *Cluc-syn*, and 3' UTRs of endogenous *Socs2* and *Nanog* fused to a *Cluc* reporter. **(d)** dCas13 targeting the 5' UTRs of endogenous *Hspa1a* and *Hsph1* attached to a *Cluc* reporter. Indicated dCas13 guide RNAs (purple) were tiled across each reporter. NT = non-targeting guide RNA; NES = nuclear export signal; NLS = nuclear localization signal. For **(b-d)** mRNA and **(d)** protein, values and error bars reflect the mean  $\pm$  s.e.m. of  $n=3$  independent biological replicates. For **(b-c)** protein, values and error bars reflect the mean  $\pm$  s.e.m. of  $n=5$  independent biological replicates.




**Supplementary Figure 6. Validation of targeted *Actb* methylation by TRM editors. (a)** MeRIP-RT-qPCR of *Actb* A1216 from HEK293T cells transfected with a vector control or full-length METTL3. **(b)** MeRIP-RT-qPCR of indicated TRM editors or TRM methyltransferase domains with *Actb*-targeting or non-targeting guide RNAs. M3 and M3M14 refer to methyltransferase components lacking dCas13. Values and error bars reflect the mean $\pm$ s.e.m. of n=3 independent biological replicates.




**Supplementary Figure 7. Cellular protein expression of TRM editors.** Representative western blots of 3×HA-tagged TRM editors compared with inactive TRM controls. HEK293T cells were co-transfected with non-targeting guide RNAs in all conditions. Editors were stained with an anti-HA antibody and histone H3 served as a loading control. Inactive TRM editors used methyltransferase-inactive M3<sup>D395</sup> instead of M3 and are indicated by active MTase (-). Every active and inactive pair from the same TRM construct comes from the same Western blot. Western blots were performed twice with similar results.



**Supplementary Figure 8. Validation of targeted *Gapdh* methylation by TRM editors. (a)** MeRIP-seq coverage of *Gapdh* mRNA from un-transfected HEK293T cells. **(b)** MeRIP-RT-qPCR of *Gapdh* A690 from HEK293T cells transfected with a control plasmid or full-length METTL3. **(c)** MeRIP-RT-qPCR of indicated TRM editors or TRM methyltransferase domains with *Gapdh*-targeting or non-targeting guide RNAs. M3 and M3M14 refer to methyltransferase components lacking dCas13. Values and error bars reflect the mean $\pm$ s.e.m. of n=4 independent biological replicates.




**Supplementary Figure 9. Validation of targeted *Foxm1* methylation by TRM editors. (a)** MeRIP-RT-qPCR of *Foxm1* 3'UTR m<sup>6</sup>A sites (A3488 and A3504) from HEK293T cells transfected with a control plasmid or full-length METTL3. **(b)** MeRIP-RT-qPCR of indicated TRM editors or TRM methyltransferase domains with *Foxm1*-targeting or non-targeting guide RNAs. M3 and M3M14 refer to methyltransferase components lacking dCas13. Values and error bars reflect the mean  $\pm$  s.e.m. of n=3 independent biological replicates.




**Supplementary Figure 10. Validation of targeted Sox2 methylation by TRM editors. (a)** MeRIP-RT-qPCR of Sox2 3'UTR m<sup>6</sup>A sites (A1398 and A1405) from HEK293T cells transfected with a control plasmid or full-length METTL3. **(b)** MeRIP-RT-qPCR of indicated TRM editors or TRM methyltransferase domains with Sox2-targeting or non-targeting guide RNAs. M3 and M3M14 refer to methyltransferase components lacking dCas13. Values and error bars reflect the mean $\pm$ s.e.m. of n=3 independent biological replicates.







**Supplementary Figure 11. Orthogonal validation of TRM with MazF-qPCR.** (a) Schematic of MazF-qPCR method for base-resolution  $m^6A$  measurement. MazF ribonuclease specifically digests ACA but not  $m^6ACA$ , allowing  $m^6A$  detection within ACA motifs by measurement of MazF digestion efficiency. Cellular RNA samples are treated with (+MazF) or without MazF (-MazF), followed by RT-qPCR of a target amplicon spanning the interrogated ACA motif. +MazF/-MazF amplicon abundance provides single-base quantification of relative  $m^6A/A$  ratios at the targeted ACA motif. (b) MazF-qPCR of *Gapdh* A690. (c) MazF-qPCR of *Sox2* A1398. Inactive TRM editors contain a methyltransferase-inactivating D395A mutation within M3. Values and error bars reflect the mean  $\pm$  s.e.m. of  $n=3$  independent biological replicates.




**Supplementary Figure 12. MeRIP-seq of *Actb* mRNA targeted by TRM editors. (a,b) *Actb* read coverage of m<sup>6</sup>A-immunoprecipitated (m<sup>6</sup>A IP) RNA from MeRIP-seq of transfected HEK293T cells. *Actb* A1216 was targeted with (a) dCas13–M3nls or (b) dCas13–M3M14nes with the following conditions: active editor with a target guide RNA, inactive editor with a target guide RNA, and active editor with a non-target guide RNA. All DRACH motifs susceptible to TRM modification are annotated as ticks underneath the IGV track. The target guide RNA (purple) and targeted A1216 site (grey) are shown. Inactive TRM editors contain a methyltransferase-inactivating D395A mutation within M3. MeRIP-seq analysis was performed with n=5 independent biological replicates.**




**Supplementary Figure 13. TRM editing window on *Actb* and *Gapdh*.** MeRIP-RT-qPCR of (a) *Actb* A1216 and (b) *Gapdh* A690 targeted by dCas13-M3nls and dCas13-M3M14nes with 30-nt guide RNAs (purple) ending at the indicated bp from the target adenine. NT = non-targeting. Inactive TRM editors contain a methyltransferase-inactivating D395A mutation within M3. Values and error bars reflect the mean  $\pm$  s.e.m. of  $n=3$  independent biological replicates.



**Supplementary Figure 14. Sequence preferences of TRM editors.** Sequence logos of m<sup>6</sup>A-enriched RNA from HEK293T cells expressing indicated constructs and guide RNAs. Logos for off-target sites from active dCas13-M3nls and dCas13-M3M14nes + *Actb* gRNA (2<sup>nd</sup> row) were created from 1,018 and 3,144 m<sup>6</sup>A peaks, respectively, not found in the inactive TRM + *Actb* gRNA conditions. All other logos were generated from the 5,000 most-methylated m<sup>6</sup>A peaks for each condition. The modified adenine is denoted as m<sup>6</sup>A below the logos. Inactive TRM editors contain a methyltransferase-inactivating D395A mutation within M3. MeRIP-seq analysis for producing sequence logos was performed with n=5 independent biological replicates.




**Supplementary Figure 15. Effect of TRM editors on cellular m<sup>6</sup>A content.** Relative m<sup>6</sup>A/A in polyA<sup>+</sup> RNA normalized to a transfected vector control. HEK293T cells were transfected with indicated TRM editors and non-targeting guide RNAs. Equal amounts of cellular mRNA were captured and detected with anti-m<sup>6</sup>A antibodies to quantify m<sup>6</sup>A/A ratios. Inactive TRM editors contain a methyltransferase-inactivating D395A mutation within M3. Values and error bars reflect the mean±s.e.m. of n=6 independent biological replicates. *P* values were calculated using a two-tailed Student's *t*-test.




**Supplementary Figure 16. Off-target methylation by TRM editors.** (a,b) Differential m<sup>6</sup>A enrichment of >21,000 methylated sites in HEK293T cells transfected with (a) dCas13–M3nls or (b) dCas13–M3M14nes and *Actb* A1216-targeting or non-target guide RNAs. Top: differential methylation of m<sup>6</sup>A sites between conditions indicated above. Only differentially methylated sites with statistical significance ( $P < 0.001$ ) are shown. Bottom: Venn diagrams depicting overlap of all methylated m<sup>6</sup>A sites for the above comparisons. (c) Overlay of dCas13–M3nls (blue) and dCas13–M3M14nes (grey) differential methylation with the following comparisons: left, active editors with *Actb* guide RNAs vs. inactive editors with *Actb* guide RNAs; right, active editors with non-target guide

RNAs vs. inactive editors with *Actb* guide RNAs. The targeted *Actb* A1216 site is outlined in black. Inactive TRM editors contain a methyltransferase-inactivating D395A mutation within M3. MeRIP-seq analysis was performed with n=5 independent biological replicates. Statistical significance was calculated using a logs likelihood-ratio test with false discovery rate correction.




**Supplementary Figure 17. Endogenous methylation levels of TRM editor off-targets.** (a) Density plot depicting the m<sup>6</sup>A enrichment ( $\log_2$  m<sup>6</sup>A IP/input) of 566 dCas13–M3nls off-target sites in a methyltransferase-inactive TRM control. 50 off-targets did not have measurable methylation in the control. (b) Density plot depicting the m<sup>6</sup>A enrichment ( $\log_2$  m<sup>6</sup>A IP/input) of 2,438 dCas13–M3M14nes off-target sites in a methyltransferase-inactive TRM control. 1,708 off-targets did not have measurable methylation in the control. MeRIP-seq analysis was performed with n=5 independent biological replicates.






**Supplementary Figure 18. Effects of TRM editors on transcriptome-wide distribution of m<sup>6</sup>A.** (a) Metagenome plots of m<sup>6</sup>A distribution within mRNA (left) and lncRNA (right) in HEK293T cells transfected with indicated TRM editors and *Actb* guide RNAs. (b,c) Bar plots depicting the percentage of m<sup>6</sup>A peaks within distinct mRNA regions, from HEK293T cells treated with the specified TRM editors and guide RNAs. *Actb* guide RNAs target the A1216 site, and *Gapdh* guide RNAs target the A690 site. 10,000 of the most-methylated m<sup>6</sup>A peaks from each sample was used for each analysis. (d,e) Transcriptome-wide distribution of off-target m<sup>6</sup>A sites from (d) dCas13–M3nls and (e) dCas13–M3M14nes, with 97.5% confidence intervals shaded in. Inactive TRM editors contain a methyltransferase-inactivating D395A mutation within M3. MeRIP-seq analysis for generating all plots was performed with n=5 independent biological replicates.




**Supplementary Figure 19. Effects of TRM editors on cellular transcriptome abundances.**

Volcano and scatter plots depict differential gene transcript abundance in HEK293T cells transfected with **(a)** dCas13-M3nls and **(b)** dCas13-M3M14nes, each compared with its corresponding inactive TRM editor using methyltransferase-inactive M3<sup>D395</sup> instead of M3. Cells were co-transfected with non-targeting guide RNAs for all conditions. Differentially expressed genes ( $P < 0.05$  and fold-change  $> 2$ ) are shown in red and counted in each volcano plot. TPM = transcripts per million. Differential RNA-seq analysis was performed with  $n = 3$  independent biological replicates, and more than 196,000 total transcripts from over 15,000 total genes were analyzed in each experiment. Statistical significance was calculated using a two-tailed Student's  $t$ -test with false discovery rate correction.



**Supplementary Figure 20. Comparison of TRM editors with M3M14–dCas9 + PAMmer editors<sup>3</sup>.** (a) *Actb* read coverage of m<sup>6</sup>A-immunoprecipitated (m<sup>6</sup>A IP) RNA fragments from MeRIP-seq of HEK293T cells transfected with indicated M3M14–dCas9 editors and single guide RNAs (sgRNAs) with corresponding PAMmers. The following conditions are shown: M3M14–dCas9 with sgRNA and PAMmers targeting *Actb* A1216 (red), M3M14–dCas9 with non-targeting sgRNA and PAMmers (blue), and inactive editor control with sgRNA and PAMmers targeting *Actb* A1216 (black outline). All DRACH motifs susceptible to TRM modification are shown as black tick marks underneath the IGV track. The target guide RNA (purple) and targeted A1216 site (grey) are shown. (b) Differential m<sup>6</sup>A enrichment of >15,000 methylated sites in HEK293T cells transfected with M3M14–dCas9 and either *Actb* A1216-targeting sgRNA or non-targeting sgRNA with corresponding PAMmers. Top: differential methylation of m<sup>6</sup>A sites between conditions indicated above. Only differentially methylated m<sup>6</sup>A sites with statistical significance ( $p < 0.01$ ) are shown. Bottom: Venn diagrams depicting overlap of all methylated m<sup>6</sup>A sites for the above comparisons. Inactive M3M14–dCas9 editor control bears a catalytically-inactivating D395 mutation within its METTL3 methyltransferase domain. MeRIP-seq analysis was performed on  $n=5$  independent biological replicates. Statistical significance was calculated using a logs likelihood-ratio test with false discovery rate correction.



**Supplementary Figure 21. *Gapdh* RNA expression changes from TRM editing.** Differential RNA expression of HEK293T cells transfected with (a) dCas13–M3nls or (b) dCas13–M3M14nes and either the *Gapdh* A690-targeting guide RNA or a non-targeting guide RNA. The targeted GAPDH gene is marked in red. Inactive TRM control indicates editors containing a methyltransferase-inactivating M3 D395A mutation with a *Gapdh*-targeting guide RNA. Non-target gRNA control indicates methyltransferase-active TRM editors with a non-targeting guide RNA. Differential RNA-seq analysis was performed with n=5 independent biological replicates. Statistical significance was calculated using a two-tailed Student's *t*-test with false discovery rate correction.

**Supplementary Table 1.** RNA oligonucleotide sequences for *in vitro* kinetics assays. The adenine susceptible to methylation is bolded within the GGACU m<sup>6</sup>A motif (red).

Name	RNA sequence
ssRNA	AGCUCGGUCCGGUUGGGUU <b>GGACU</b> GAAUAUGGAUUACUUGGUAGAA

**Supplementary Table 2.** Cas13 guide RNA spacer sequences used in this study. A guanosine (lower-case g) was added to the 5' end of 30-nt guide RNA spacers (upper-case sequences) used in HEK293T cells, because the human U6 promoter has a strong preference for G at the transcription start site. TRM = targeted RNA methylation. IF = immunofluorescence.

Name	Guide RNA spacer sequence	Figures used in
Synthetic target guide	TGCAGAGTAGAGGCCGCAGGATAGTTTAGAAC	2c,d; SI 3
Non-targeting guide ( <i>E. coli</i> )	GTAATTCCTGGTCCGTCGACGCATAGTCTG	2c
Non-targeting guide (HEK293T)	gGTAATGCCTGGCTTGTCGACGCATAGTCTG	3b-c; 4a-e; 5a-e; 6a-d; SI 4a-b; SI 5b-d; SI 6b; SI 7; SI 8c; SI 9b; SI 10b; SI 11b-c; SI 12a-b; SI 13a-b; SI 14; SI 15; SI 16a-c; SI 18a-c; SI 19a-b; SI 21a-b
<i>Cluc-syn</i> guide 1	gTAGTCCGAGTCCAGTCCGGAGTCCGAGCAT	SI 5c
<i>Cluc-syn</i> guide 2	gTTCCAAACTATCCTGCGGCCTCTACTCTGC	3b; SI 5c
<i>Cluc-Socs2</i> guide 1	gTACATAGCTGCATTCGGAGATACTCTATGT	3c; SI 4a-b; SI 5c
<i>Cluc-Socs2</i> guide 2	gGATAAAACGCGACTTCAGCCTTTACATGCG	SI 5c
<i>Actb</i> guide IF	gGGGGGATGCTCGCTCCAACCGACTGCTGTC	4a
<i>Actb</i> A1216 guide -1	gCCGCCTAGAAGCATTGCGGTGGACGATGG	SI 13a
<i>Actb</i> A1216 guide -8	gGAAGCATTGCGGTGGACGATGGAGGGGCC	4b; 6a,b; SI 6b; SI 12a-b; SI 13a; SI 14; SI 16a-c; SI 18a-b
<i>Actb</i> A1216 guide -15	gTTGCGGTGGACGATGGAGGGGCCGACTCG	SI 13a
<i>Actb</i> A1216 guide -22	gGGACGATGGAGGGGCCGACTCGTCATACT	SI 13a
<i>Gapdh</i> A690 guide -1	gTCTGGAGAGCCCCGCGGCCATCACGCCACA	SI 13b
<i>Gapdh</i> A690 guide -8	gAGCCCCGCGGCCATCACGCCACAGTTTCCC	4c; 5a-e; SI 8c; SI 11b; SI 13b; SI 17a-b; SI 18c-e; SI 21a-b
<i>Gapdh</i> A690 guide -15	gCGGCCATCACGCCACAGTTTCCCGGAGGGG	SI 13b
<i>Gapdh</i> A690 guide -22	gCACGCCACAGTTTCCCGGAGGGGCCATCCA	SI 13b
<i>Foxm1</i> A3488, A3504 guide	gGTATGATTGGGGACATTATCAGAGAAACAT	4d, SI 9b
<i>Sox2</i> A1398, A1405 guide	gTCACATGTGTGAGAGGGGCAGTGTGCCGTT	4e, SI 10b; SI 11c
<i>Cluc</i> CDS guide 1	gAGGTTCTCCAGGGTGATGGACACCTTCCAG	SI 5b
<i>Cluc</i> CDS guide 2	gGTCTGTATCTTCCATCATTTTAAGATCTCC	SI 5b
<i>Cluc</i> CDS guide 3	gAATTGGTATCTTGCTTTGTCAAATGTATCG	SI 5b
<i>Cluc</i> CDS guide 4	gATGGATCTCTAATATGTACGACGAGCAGTT	SI 5b
<i>Cluc</i> CDS guide 5	gTACTTCTAGGGTGTCTCCATGCTTTATGTA	SI 5b
<i>Cluc-Nanog</i> guide 1	gGCCAGTGTCCAGACTGAAATTGAGTAATAT	SI 5c
<i>Cluc-Nanog</i> guide 2	gCACTCCAGCCTGGGCGACAGAGCAAGACTC	SI 5c
<i>Hspa1a-Cluc</i> guide 1	gGGGAAGCCTTGGGACAACGGGAGTCACTCT	SI 5d
<i>Hspa1a-Cluc</i> guide 2	gGGAACACTGGATCCGCGAGAAGAGCTCGGT	SI 5d
<i>Hsph1-Cluc</i> guide 1	gCCTCAGCCTTATGTATCGCACTGATCAGAA	SI 5d
<i>Hsph1-Cluc</i> guide 2	gCTCCGGCCCCCTGCCTGCTTCTCCTGCCGC	SI 5d

<i>Brd8</i> guide 1	gTGAAGCATCCTGTTTGCGGGTAGAATCTCT	6c
<i>Znf638</i> guide 1	gAAATGTGTAAGCCTGACATCTTGGTTCCAC	6d

**Supplementary Table 3.** Cas9 guide RNA spacer and PAMmer sequences used for experiments with M3M14-dCas9<sup>3</sup>. A guanosine (lower-case g) was added to the 5' end of 20-nt single guide RNA (sgRNA) spacers (upper-case sequences) used in HEK293T cells, because the human U6 promoter has a strong preference for G at the transcription start site.

Name	Sequence
M3M14-dCas9 <i>Actb</i> sgRNA	gCACCGCAAATGCTTCTAGGC
M3M14-dCas9 non-targeting sgRNA	gGTATTACTGATATTGGTGGG
M3M14-dCas9 <i>Actb</i> PAMmer	mUTmGCmGGmUGmUGGmGAmUGmGAmGGmGGmCCmGGmAC
M3M14-dCas9 non-targeting PAMmer	mGCmGGmAGmGAmGCTmUGmCGmAGmCGmGTmGGmUTmGG



**Supplementary Table 4.** Sequences of guide-quenching DNA oligonucleotides. Because guide RNAs interfere with RT-qPCR of targeted transcripts, DNA oligos were used to quench guides within total RNA purified from HEK293T cells. DNA oligos were designed to hybridize with guide RNA spacer sequences and the PspCas13b crRNA hairpin. The constant crRNA-binding region is shown in lower-case. A 2',3'-dideoxycytidine modification (/3ddc/) hybridizes with the guide RNA's 5' G and prevents polymerase extension of the guide-quenching oligo in subsequent reverse-transcription and PCR reactions.

<b>Guide RNA name</b>	<b>Guide-quenching DNA oligo sequence</b>
Non-targeting guide (HEK293T)	ggaccttcacaacCAGACTATGCGTCGACAAGCCAGGCATTAC/3ddc/
<i>Cluc-syn</i> guide 1	ggaccttcacaacGCAGAGTAGAGGCCGCAGGATAGTTTGGAA/3ddc/
<i>Cluc-Socs2</i> guide 1	ggaccttcacaacACATAGAGTATCTCCGAATGCAGCTATGTA/3ddc/
<i>Actb</i> A1216 guide -1	ggaccttcacaacCCATCGTCCACCGCAAATGCTTCTAGGCGG/3ddc/
<i>Actb</i> A1216 guide -8	ggaccttcacaacGGCCCCTCCATCGTCCACCGCAAATGCTTC/3ddc/
<i>Actb</i> A1216 guide -15	ggaccttcacaacCGAGTCCGGCCCCTCCATCGTCCACCGCAA/3ddc/
<i>Actb</i> A1216 guide -22	ggaccttcacaacAGTATGACGAGTCCGGCCCCTCCATCGTCC/3ddc/
<i>Gapdh</i> A690 guide -1	ggaccttcacaacTGTGGCGTGATGGCCGCGGGGCTCTCCAGA/3ddc/
<i>Gapdh</i> A690 guide -8	ggaccttcacaacGGGAAACTGTGGCGTGATGGCCGCGGGGCT/3ddc/
<i>Gapdh</i> A690 guide -15	ggaccttcacaacCCCCTCCGGGAAACTGTGGCGTGATGGCCG/3ddc/
<i>Gapdh</i> A690 guide -22	ggaccttcacaacTGGATGGCCCCTCCGGGAAACTGTGGCGTG/3ddc/
<i>Foxm1</i> A3488, A3504 guide	ggaccttcacaacATGTTTCTCTGATAATGTCCCAATCATAC/3ddc/
<i>Sox2</i> A1398, A1405 guide	ggaccttcacaacAACGGCACACTGCCCTCTCACACATGTGA/3ddc/

**Supplementary Table 5.** Primers used for RT-qPCR in TRM methylation assays, mazF, or dCas13 targeting experiments. All probes were synthesized from Bio-Rad and used for TaqMan qPCR.

Name	Sequence
Synthetic target forward	CCGCAGGATAGTTTGG AACATGGACT
Synthetic target reverse	GGCCGCGGGGATCCAGACAT
Synthetic target probe	/56-FAM/CTTTGGACTTGATGAGCGGCCGCGGG/3IABkFQ/
<i>Cluc-syn</i> forward	GAAGAAACCCGTGGCCAAGATGCTC
<i>Cluc-syn</i> reverse	GAACATGGACTCTAGGACTGGACTTTG
<i>Cluc-syn</i> probe	/56-FAM/CCGGACTGGACTCGGACTAATGCAGAGTAGAGG/3IABkFQ/
<i>Cluc-Socs2</i> forward	GGGGACTGCCTTTACCAACAAGACTAAAA
<i>Cluc-Socs2</i> reverse	CTCAAGTTTTGGTTCTCTTTTACATAGCTGCATTC
<i>Cluc-Socs2</i> probe	/56-FAM/CCAGGTATAAATGTTTCTCTTTTTTAAACATGTCTCACATAGAGTATCTCC/3IABkFQ/
<i>Actb</i> A1216 target 1 forward	ATCGTCCACCGCAAATGCTT
<i>Actb</i> A1216 target 1 reverse	TCATCTTGTCTTCTGCGCAAGT
<i>Actb</i> A1216 target 1 probe	/56-FAM/AGTCCGCCT/ZEN/AGAAGCATTTGCGGT/3IABkFQ/
<i>Actb</i> A1216 target 2 forward	TCCATCGTCCACCGCAAAT
<i>Actb</i> A1216 target 2 reverse	TTGTTTTCTGCGCAAGTTAGGT
<i>Actb</i> A1216 target 2 probe	/5HEX/CCGCCTAGA/ZEN/AGCATTGCGGTGG/3IABkFQ/
<i>Actb</i> reference control forward	Bio-Rad qHsaCEP0036280
<i>Actb</i> reference control reverse	Bio-Rad qHsaCEP0036280
<i>Actb</i> reference control probe	Bio-Rad qHsaCEP0036280 (Cy5-labeled)
<i>Gapdh</i> A690 target forward	CATCACTGCCACCCAGAAGA
<i>Gapdh</i> A690 target reverse	CAGTAGAGGCAGGGATGATGTT
<i>Gapdh</i> A690 target probe	/56-FAM/CCCTCCGGG/ZEN/AAACTGTGGCGT/3IABkFQ/
<i>Gapdh</i> reference control forward	TCAAGGCTGAGAACGGGAAG
<i>Gapdh</i> reference control reverse	GGACTCCACGACGTA CT CAG
<i>Gapdh</i> reference control probe	/5Cy55/TCCAGGAGCGAGATCCCTCC/3IAbRQSp/
<i>Foxm1</i> A3488, A3504 target 1 forward	TGCCCAGATGTGCGCTATTA
<i>Foxm1</i> A3488, A3504 target 1 reverse	CTTCTCAAGCCTCCACCTGA
<i>Foxm1</i> A3488, A3504 target 1 probe	/56-FAM/TCGTCAATG/ZEN/CCAGTCTCCCTGGT/3IABkFQ/
<i>Foxm1</i> A3488, A3504 target 2 forward	GTGCCCAGATGTGCGCTAT
<i>Foxm1</i> A3488, A3504 target 2 reverse	GTCAATGCCAGTCTCCCTGG
<i>Foxm1</i> A3488, A3504 target 2 probe	/5HEX/CCAATCAT/ZEN/ACCAGGGAGACTGGCA/3IABkFQ/

<i>Foxm1</i> reference control forward	Bio-Rad qHsaCEP0050615
<i>Foxm1</i> reference control reverse	Bio-Rad qHsaCEP0050615
<i>Foxm1</i> reference control probe	Bio-Rad qHsaCEP0050615 (Cy5-labeled)
<i>Sox2</i> A1398, A1405 target 1 forward	GGCCATTAACGGCACACTG
<i>Sox2</i> A1398, A1405 target 1 reverse	TCTTTTGCACCCCTCCCATT
<i>Sox2</i> A1398, A1405 target 1 probe	/56-FAM/TCACACATG/ZEN/TGAGGGCCGGACAG/3IABkFQ/
<i>Sox2</i> A1398, A1405 target 2 forward	CGGCCATTAACGGCACACT
<i>Sox2</i> A1398, A1405 target 2 reverse	CCCTCCCATTTCCCTCGTTTT
<i>Sox2</i> A1398, A1405 target 2 probe	/5HEX/CATGTGAGG/ZEN/GCCGGACAGCGAAC/3IABkFQ/
<i>Sox2</i> reference control forward	Bio-Rad qHsaCEP0039595
<i>Sox2</i> reference control reverse	Bio-Rad qHsaCEP0039595
<i>Sox2</i> reference control probe	Bio-Rad qHsaCEP0039595 (Cy5-labeled)
<i>Sox2</i> A1398, A1405 MazF target forward	CATGTGAGGGCCGGACAG
<i>Sox2</i> A1398, A1405 MazF target reverse	TCTTTTGCACCCCTCCCATT
<i>Sox2</i> A1398, A1405 MazF target probe	/56-FAM/CGAGGGAAA/ZEN/TGGGAGGGGTGCAAA/3IABkFQ/
<i>Sox2</i> MazF reference control forward	CATGGGTTTCGGTGGTCAAG
<i>Sox2</i> MazF reference control reverse	TGGAGTGGGAGGAAGAGGTA
<i>Sox2</i> MazF reference control probe	/5Cy5/TCCGAGGCCAGCTCCAGCCC/3IAbRQSp/
EEF1A1 m <sup>6</sup> A <sup>+</sup> control forward	CGGTCTCAGAACTGTTTGTTC
EEF1A1 m <sup>6</sup> A <sup>+</sup> control reverse	AAACCAAAGTGGTCCACAAA
EEF1A1 m <sup>6</sup> A <sup>+</sup> control probe	/5TEX615/CGTAAACCTTCAGAAGGAAAGGAG/3IAbRQSp/
EEF1A1 m <sup>6</sup> A <sup>-</sup> control forward	GGATGGAAAGTCACCCGTAAG
EEF1A1 m <sup>6</sup> A <sup>-</sup> control reverse	TTGTCAGTTGGACGAGTTGG
EEF1A1 m <sup>6</sup> A <sup>-</sup> control probe	/5Cy55/AACCACGCTGCTTGAGGCTC/3IAbRQSp/
<i>Cypridina</i> luciferase forward	ACTGTAAACGGTGGAGCTGA
<i>Cypridina</i> luciferase reverse	AAGCCTGGCATCTCAACAAC
<i>Cypridina</i> luciferase probe	/5Cy5/TCGGCGAGGTCACCATCGCT/3IAbRQSp/
<i>Gaussia</i> luciferase forward	ATCTGCCTGTCCACATCAA
<i>Gaussia</i> luciferase reverse	CGGACTCTTTGTGCCTTC

*Gaussia* luciferase probe

/56-FAM/CCCAGGACG/ZEN/CTGCCACACCT/3IABkFQ/

**Supplementary Table 6.** Primers used for semi-quantitative PCR in alternative splicing assays.

<b>Name</b>	<b>Sequence</b>
<i>Znf638</i> exon 1 forward	CGTCGAGACTGGAGGCTGAG
<i>Znf638</i> exon 3 reverse	TGAGTAGATGTATTTTGATGCTGAATCC
<i>Brd8</i> exon 20 forward	GAGAGATTCTACCCGCAAACAGG
<i>Brd8</i> exon 22 reverse	TATCTGCTTCAATGGCACAGCGG

**Supplementary Sequences 1.** Amino acid sequences of nucleus- and cytoplasm-localized TRM editors. Color coding is as follows:

green = HIV nuclear export signal

red = bipartite SV40 nuclear localization signal

blue = PspCas13b Δ984-1090 H133A (dCas13)

black = linkers

orange = METTL3<sup>273-580</sup> (for dCas13–M3nes and dCas13–M3nls) or METTL3<sup>359-580</sup> (for dCas13–M3M14nes and dCas13–M3M14nls)

brown = METTL14<sup>111-456</sup>

**dCas13–M3nes:**

MNIPALVENQKKYFGTYSVMAMLNAQTVLDHIQKVADIEGEQNNENNLFWHPVMSHLYNAKNGYD  
KQPEKTMFIERLQSYFPFLKIMAENQREYSNGKYKQNRVEVNSNDIFEVLKRAFGVLKMYRDLTNAY  
KTYEEKLNDGCEFLTSTEQPLSGMINNYTVALRNMNERYGYKTEDLAFIQDKRFKFKVFKDAYGKKKS  
QVNTGFFLSLQDYNGDTQKKLHLSGVGIALLICLFLDKQYINIFLSRLPIFSSYNAQSEERRIIIRSF  
GINSIKLPKDRIHSEKSNKSVAMDMLNEVKRCPDELFTTLSAEKQSRFRIISDDHNEVLMKRSSDRFV  
PLLLQYIDYGKLFDFHIRFHVNMGKLRYPVLLKADKTCIDGQTRVVRVIEQPLNGFGRLEEAETMRKQ  
ENGTFGNSGIRIRDFENMKRDDANPANYPYIVDTYTHYLENNKVEMFINDKEDSAPLLPVIEDDRYV  
VKTIPSCRMSTLEIPAMAFHMFLFGSKKTEKLIVDVHNRYKRLFQAMQKEEVTAENIASFGIAESDLP  
QKILDLSIGNAHGKDVDFAFIRLTVDMLTDTERRIKRFKDDRKSIRSADNKMGRGFKQISTGKLADFL  
AKDIVLFQPSVNDGENKITGLNYRIMQSAIAVYDSGDDYEAKQQFKLMFEKARLIGKGTTEPHPLYK  
VFARSIPANAVEFYERYLIERKFYLTGLSNEIKKGNRVDVPFIRRDQNKWKTPAMKTLGRIYSEDLP  
VELPRQMFDNEIKSHLKSPLQMEGIDFNANVTYLIAEYMKRVLDDDFQTFYQWNRNYRYMDMLKGE  
YDRKGSQHCFTSVEEREGLWKERASRTERYRKQASNKIRSNRQMRNASSEIEITLDRKLSNSRNEYQK  
SEKVI RRYRVQDALLFLLAKKTLTELADFDGERFKLKEIMPDAEKGILSEIMPMSFTFEKGGKKTIT  
SEGKMLKNYGDDFFVLASDKRIGNLLELVGSDIVSKEDGSLQLPPLERLTLGSGSETPGTSESATPES  
QEFCDYGTKEECMKASDADRPCRKLHFRRRIINKHTDESLGDCSFLNTCFHMDTCKYVHYEIDACMD  
SEAPGSKDHTPSQELALTQSVGGDSSADRLFPPQWICCDIRYLDVSILGKFAVVMADPPWDIHMEL  
PYGTLTDDERMRLNIPVLQDDGFLFLWWTGRAMELGRECLNLWGYERVDEIIVWVKTNQLQRIIRT  
GRTGHWLNHGKEHCLVGVKGNPQGFNQGLDCDVIVAEVRSTSHKPDEIYGMIERLSPGTRKIELF  
GRPHNVQPNWITLGNQLDGIHLLDPDVARFKQRYPDGIISKPKNL

**dCas13–M3nls:**

MKRTADGSEFESPKKKRKVNIPALVENQKKYFGTYSVMAMLNAQTVLDHIQKVADIEGEQNNENNLF  
WHPVMSHLYNAKNGYDKQPEKTMFIERLQSYFPFLKIMAENQREYSNGKYKQNRVEVNSNDIFEV  
LKRAFGVLKMYRDLTNAYKTYEEKLNDGCEFLTSTEQPLSGMINNYTVALRNMNERYGYKTEDLAF  
IQDKRFKFKVFKDAYGKKKSQVNTGFFLSLQDYNGDTQKKLHLSGVGIALLICLFLDKQYINIFLS  
RLPIFSYNAQSEERRIIIRSFGINSIKLPKDRIHSEKSNKSVAMDMLNEVKRCPDELFTTLSAEKQ  
SRFRIISDDHNEVLMKRSSDRFVPLLLQYIDYGKLFDFHIRFHVNMGKLRYPVLLKADKTCIDGQ  
TRVVRVIEQPLNGFGRLEEAETMRKQENGTFGNSGIRIRDFENMKRDDANPANYPYIVDTYTHY  
LENNKVEMFINDKEDSAPLLPVIEDDRYVVKTIPSCRMSTLEIPAMAFHMFLFGSKKTEKLIVD  
VHNRYKRLFQAMQKEEVTAENIASFGIAESDLPQKILDLSIGNAHGKDVDFAFIRLTVDMLTD  
TERRIKRFKDDRKSIRSADNKMGRGFKQISTGKLADFLAKDIVLFQPSVNDGENKITGLNYRIMQ  
SAIAVYDSGDDYEAKQQFKLMFEKARLIGKGTTEPHPLYKVFARSIPANAVEFYERYLIERKFY  
LTGLSNEIKKGNRVDVPFIRRDQNKWKTPAMKTLGRIYSEDLPVELPRQMFDNEIKSHLKSPLQ  
MEGIDFNANVTYLIAEYMKRVLDDDFQTFYQWNRNYR

YMDMLKGEYDRKGS LQHCFTSVEEREGLWKERASRTERYRKQASNKIRSNRQMRNASSEEIETILD  
KRLSNSRNEYQKSEKVI RRYRVQDALLFLLAKKTLTELADFDGERFKLKEIMPDAEKGILSEIMPMSFT  
FEKGGKKYTITSEGMKLKNYGDFV LASDKRIGNLLELVGSDIVSKEDGSKRTADGSEFEPKKKRKVS  
GSETPGTSESATPESQEFCDYGTKEECMKASDADRPCRKLHFRRINKHTDESLGDCSFLNTCFHM  
DTCKYVHYEIDACMDSEAPGSKDHTPSQELALTQSVGGDSSADRLFPPQWICCDIRYLDVSI LGKFA  
VVMADPPWDIHMELPYGTLT DDEMRR LNIPVLQDDGFLFLWWTGRAMELGRECLNLWGYERVDEII  
WVKTNQLQRIIRTGRTGHWLNHGKEHCLVGVKGNPQGFNQGLDCDVIVAEVRSTSHKPDEIYGMIE  
RLSPGTRKIELFGRPHNVQPNWITLGNQLDGIHLLDPDVVARFKQRYPDGIISKPKNL

dCas13–M3M14nes:

MNIPALVENQKKYFGTYSVMAMLNAQTVLDHIQKVADIEGEGQNENNENLWFHPVMSHLYNAKNGYD  
KQPEKTMFIERLQSYFPFLKIMAENQREYSNGKYKQNRVEVNSNDIFEVLKRAFGVLKMYRDLTNAY  
KTYEEKLNDGCEFLTSTEQPLSGMINNYTVALRNMNERYGYKTEDLAFIQDKRFKFKV DAYGKKKS  
QVNTGFFLSLQDYNGDTQKKLHLSGVGIAL LICLFLDKQYINIFLSRLPIFSSYNAQSEERRIIIRSF  
GINSIKLPKDRIHSEKSNKSVAMDMLNEVKRCPDELFTTLSAEKQSRFRIISDDHNEVLMKRSSDRFV  
PLLLQYIDYGKLFDFHIRFHVNMGKLR YLLKADKTCIDGQTRVRVIEQPLNGFGRLEEAE TMRKQEN  
GTFGNSGIRIRDFENMKRDDANPANYPIVDTYTHYLENNKVEMFINDKEDSAPLLPVIEDDRYVVK  
TIPSCRMSTLEIPAMAFHMFLFGSKKTEKLIVDVHNRYKRLFQAMQKEEVTAENIASFGIAESDLP  
QKILDLSIGNAHGKD VDAFIRLTVDDMLTDTERRIKRFKDDRKSIRSADNKMGRGFKQISTGKLAD  
FLAKDIVLFQPSVNDGENKITGLNYRIMQSAIAVYDSGDDYEAKQQFKLMFEKARLIGKGTTEPH  
PFLYKVFARSIPANAVEFYERYLIERKFYLTGLSNEIKKGNRVDVPIRRDQNKWKTPAMKTLGR  
IYSEDLPVELPRQMFDNEIKSHLKS LPQMEGIDFNANVTYLIAEYMKRVLDDDFQTFYQWNR  
NYRYMDMLKGEYDRKGS LQHCFTSVEEREGLWKERASRTERYRKQASNKIRSNRQMRNASSEE  
IETILDKRLSNSRNEYQKSEKVI RRYRVQDALLFLLAKKTLTELADFDGERFKLKEIMPDAEK  
GILSEIMPMSFTFEKGGKKYTITSEGMKLKNYGDFV LASDKRIGNLLELVGSDIVSKEDGSLQL  
PPLERLTLSSGSSGGSSGSETPGTSESATPESGGSSGGSSVGGDSSADRLFPPQWICCDIRY  
LDVSI LGKFAVVMADPPWDIHMELPYGTLT DDEMRR LNIPVLQDDGFLFLWWTGRAMELGRE  
CLNLWGYERVDEIIWVKTNQLQRIIRTGRTGHWLNHGKEHCLVGVKGNPQGFNQGLDCDVIVAE  
VRSTSHKPDEIYGMIERLSPGTRKIELFGRPHNVQPNWITLGNQLDGIHLLDPDVVARFKQRY  
PDGIISKPKNLGGSSGGSSGGSSGGSSGGSSGGSSGGSSGGSSGGSSGQSLNP  
HNDYCQH FVDTGHRPQN FIRDVGLADRFE EYPKLRELIRLKD ELIAKSNTPPMYLQADIEAFD  
IRELTPKFDVILLEPPEEYYRETGITANEKCWTWDDIMKLEIDEIAAPRSFIFLWCGSGEGLD  
LGRVCLRKWWGYRRCEDICWIKTNKNNPGKTKTLDPKAVFQRTKEHCLMGIKGTVKRSTDGDFI  
HANVDIDLIIITEEPEIGNIEKPVEIFHIIEHFCLGRRRLHLFGRDSTIRPGWLTVGPTLTNSNY  
NAETYASYFSAPNSYLTGCTEEIERLRPKSPPPKSKSDRGGGAPRGGGRGGTSAGRGRERNRSN  
FRGERGGFRGGRRGGAHRGGFPPR

dCas13–M3M14nls:

MKRTADGSEFEPKKKRKVNIPALVENQKKYFGTYSVMAMLNAQTVLDHIQKVADIEGEGQNENNENL  
WFHPVMSHLYNAKNGYDKQPEKTMFIERLQSYFPFLKIMAENQREYSNGKYKQNRVEVNSNDIFEV  
LKRAFGVLKMYRDLTNAYKTYEEKLNDGCEFLTSTEQPLSGMINNYTVALRNMNERYGYKTEDLAF  
IQDKRFKFKV DAYGKKKSQVNTGFFLSLQDYNGDTQKKLHLSGVGIAL LICLFLDKQYINIFLSRL  
PIFSYNAQSEERRIIIRSF GINSIKLPKDRIHSEKSNKSVAMDMLNEVKRCPDELFTTLSAEKQ  
SRFRIISDDHNEVLMKRSSDRFVPLLLQYIDYGKLFDFHIRFHVNMGKLR YLLKADKTCIDGQ  
TRVRVIEQPLNGFGRLEEAE TMRKQENGTFGNSGIRIRDFENMKRDDANPANYPIVDTYTHY  
LENNKVEMFINDKEDSAPLLPVIEDDRYVVK TIPSCRMSTLEIPAMAFHMFLFGSKKTEKLIV  
DVHNRYKRLFQAMQKEEVTAENIAS

FGIAESDLPQKILD LISGNAHGKDVDAFIRLTVDDMLTD TERRIKRFKDDRKSIRSADNKMGRGFKQI  
STGKLADFLAKDIVLFQPSVNDGENKITGLNYRIMQSAIAVYDSGDDYEAKQQFKLMFEKARLIGKGT  
TEPHPFlyKVFARSIPANAVEFYERYLIERKFYLTGLSNEIKKGNRVDVVPFIRRDQNKWKTPAMKTLG  
RIYSEDLVELPRQMF DNEIKSHLKS LPQMEGIDFNANVTYLIAEYMKRVLDDDFQTFYQWNRNYR  
YMDMLKGEYDRKGS LQHCFTSVEEREGLWKERASRTERYRKQASNKIRSNRQMRNASSEIETILD  
KRLSNSRNEYQKSEKVIRRYRVQDALLFLLAKKTLTELADFDGERFKLKEIMPDAEKGILSEIMPMSFT  
FEKGGKKYTITSEGMKLKNYG DFFVLASDKRIGNLLELVGSDIVSKEDGSKRTADGSEFEPKKKRKVS  
GGSSGGSSGSETPGTSESATPESSGGSSGGSVGGDSSADRLFPPQWICCDIRYLDV SILGKFAVVM  
ADPPWDIHMELPYGTLT DDEMRRLNIPVLQDDGFLFLWVTGRAMELGRECLNLWGYERVDEIIVVKT  
NQLQRIIRTGRTGHWLNHGKEHCLVGVKGNPQGFNQGLDCDVIVAEVRSTSHKPDEIYGMIERLSPG  
TRKIELFGRPHNVQPNWITLGNQLDGIHLLDPDVVARFKQRYPDGIISKPKNLGGSSGGSSGGSSGG  
SSGGSSGGSSGGSSGGSSGQSLNPHNDY CQHFVDTGHRPQNFIRDVGLADRFE EYPKLRELIRLKDELI  
AKSNTPPMYLQADIEAFDIRELTPKFDVILLEP PLEEYYRETGITANEKCWTWDDIMKLEIDEIAAPRSFI  
FLWCGSGEGLDLGRVCLRKWGYRR CEDICWIKTNKNNPGKTKTLDPKAVFQRTKEHCLMGIKGTVK  
RSTDGDFIHANVDIDLIIITEEPEIGNIEKPVEIFHIIEHFCLGRRRLHLFGRDSTIRPGWLT VGPTLTNSNY  
NAETYASYFSAPNSYLTGCTEEIERLRPKSPPPKSKSDRGGGAPRGGGRRGGTSAGRGRERNRSNF  
RGERGGFRGGRGGAHRGGFPPR



**Supplementary Sequences 2.** Sequences of exogenous reporter transcripts targeted by TRM editor constructs. Color coding is as follows:

black = reporter sequence, with the TRM guide RNA-targeted protospacer underlined

green = *Cypridina* luciferase CDS

red = targeted m<sup>6</sup>A motifs (DRACH), with target adenines marked in **bold**

Synthetic target (*E. coli* Tuner DE3):

ACCGACCAGAAUCAUGCAAGUGCGUAAGAUAGUCGCGGGCCGGGGAGTTTAATACGACTCACT  
ATAGGGGAATTGTGAGCGGATAACAATTCCCCCTCTAGAAATAATTTTGTTTAACATTTAAATCGG  
**ACUCCGGACUGGACUCGGACU**AAUGCAGAGUAGAGGCCGCAGGAUAGUUUGGAACAUGGAC  
UCUAGGACUGGACUUUGGACUUGUGUUUAUCCGCUCACAAUCCACACAACAUACGAGCCGG  
AAGCAUAAAGTGACTTCCCATCTCCGGTTTAAACAGGCCTGCATGCAGCGTAATCATGGTCATTA  
ATTAACCTCCTGTGTGAAATTGTTATCCGCTCTGCGTTAGCAATTTAACTGTGAACCGACCAGAA  
UCAUGCAAGUGCGUAAGAUAGUCGCGGGCCGGGGAGTT

Cluc-syn (HEK293T):

AUGAAGACCUUAAUUCUUGCCGUUGCAUJAGUCUACUGCGCCACUGUUCAUUGCCAGGACUG  
UCCUUAACGAACCGAUCCACCAAACACAGUCCAACUUCUGUGAAGCUAAAGAAGGAGAAUG  
UAUUGAUAGCAGCUGUGGCACCUGCACGAGAGACAUACUAUCAGAUGGACUGUGUGAAAUA  
AACCAGGAAAACAUGUUGUCGAAUGUGUCAGUAUGUAAUUGAAUGCAGAGUAGAGGCCGCA  
GGAUGGUUAGAACAUCUAUGGAAAGAGAUUCCAGUUCAGGAACCGGUACAUCGUGUU  
GGUCAAGGAACCAAGGGCGGCGACUGGAAGGUGUCCAUCACCCUGGAGAACCUGGAUGGA  
ACCAAGGGGGCUGUGCUGACCAAGACAAGACUGGAAGUGGCUGGAGACAUCAUUGACAUCGC  
UCAAGCUACUGAGAAUCCCAUCACUGUAAACGGUGGAGCUGACCCUAUCAUCGCCAACCCGU  
ACACCAUCGGCGAGGUCACCAUCGCUGUUGUUGAGAUGCCAGGCUUCAACAUCACCGUCAU  
GAGUUCUCAAACUGAUCGUGAUCGACAUCUCGGAGGAAGAUUCUGUAAGAAUCGCCCCAGA  
CACAGCAAACAAGGAAUGAUCUCUGGCCUCUGUGGAGAUUUAAAUGAUGGAAGAUACAG  
ACUUCACUUCAGAUCCAGAACAACUCGCUAUUCAGCCUAAGAUAACCAGGAGUUUGACGGU  
UGUCCACUCUAUGGAAAUCCUGAUGACGUUGCAUACUGCAAAGGUCUUCUGGAGCCGUACAA  
GGACAGCUGCCGCAACCCCAUCAACUUCUACUACACCAUCUCCUGCGCCUUCGCCCGCU  
GUAUGGGUGGAGACGAGCGAGCCUCACACGUGCUGCUUGACUACAGGGAGACGUGCGCUGC  
UCCGAAACUAGAGGAACCGUGCGUUUUGUCUGGACAUCUUCUACGAUACAUUUGACAAG  
CAAGAUACCAAUUCCAGGGUCCUGCAAGGAGAUUCUUAUGGCCGCCGACUGUUUCUGGAAC  
ACUUGGGAUGUGAAGGUUUCACACAGGAAUGUUGACUCUACACUGAAGUAGAGAAAGUACG  
AAUCAGGAAACAUCGACUGUAGUAGAACUCAUUGUUGAUGGAAAACAGAUUCUGGUUGGAG  
GAGAAGCCGUGUCCGUCCGUACAGCUCUCAGAACACUCCAUCUACUGGCAAGAUGGUGAC  
AUACUGACUACAGCCAUCCUACCUGAAGCUCUGGUGGUCAAGUUCAACUUCAAGCAACUGCU  
CGUCGUACAUAUUAGAGAUCCAUUCGAUGGUAAGACUUGCGGUUUUGCGGUAACUACAACC  
AGGAUUUCAGUGAUGAUUCUUUUGAUGCUGAAGGAGCCUGUGAUCUGACCCCAACCCACCG  
GGAUGCACCGAAGAACAGAAACCUGAAGCUGAACGACUCUGCAAUAGUCUCUUCGCCGGUCA  
AAGUGAUCUUGAUCAGAAUGUAACGUGUGCCACAAGCCUGACCGUGUCGAACGAUGCAUGU  
ACGAGUAUUGCCUGAGGGGACAACAGGGUUUCUGUGACCACGCAUGGGAGUUCAAGAAAGAA  
UGCUAUAUAAAGCAUGGAGACACCCUAGAAGUACCAGAUGAAUGCAAUAAUUGCUC**GGACUC**  
**CGGACUGGACUCGGACU**AAUGCAGAGUAGAGGCCGCAGGAUAGUUUGGAACAUG**GGACUC**UA  
GGACUG**GGACU**UU**GGACU**UGAUGAGCGGCCCGCGGGGAUCCAGACAUGA

Cluc-Socs2 (HEK293T):

AUGAAGACCUUAAUUCUUGCCGUUGCAUUAUGUCUACUGCGCCACUGUUCAUUGCCAGGACUG  
UCCUACGAACCUGAUCCACCAAACACAGUCCAACUCCUGUGAAGCUAAAAGAAGGAGAAUG  
UAUUGAUAGCAGCUGUGGCACCUGCACGAGAGACAUACUAUCAGAUGGACUGUGUGAAAAUA  
AACCAGGAAAAACAUGUUGUCGAAUGUGUCAGUAUGUAAUUGAAUGCAGAGUAGAGGCCGCA  
GGAUGGUUUAGAACAUCUAUGGAAAGAGAUUCCAGUUCAGGAACCUGGUACAUCGUGUU  
GGGUCAAGGAACCAAGGGCGGCGACUGGAAGGUGUCCAUCACCCUGGAGAACCUGGAUGGA  
ACCAAGGGGGCUGUGCUGACCAAGACAAGACUGGAAGUGGCUGGAGACAUCAUUGACAUCGC  
UCAAGCUACUGAGAAUCCCAUCACUGUAAACGGUGGAGCUGACCCUAUCAUCGCCAACCCGU  
ACACCAUCGGCGAGGUCACCAUCGCUGUUGUUGAGAUGCCAGGCUUCAACAUCACCGUCAUU  
GAGUUCUCAAACUGAUCGUGAUCGACAUCUCGGAGGAAGAUCUGUAAGAAUCGCCCCAGA  
CACAGCAAACAAGGAAUGAUCUCUGGCCUCUGUGGAGAUUUAAAUGAUGGAAGAUACAG  
ACUUCACUUCAGAUCCAGAACAACUCGCUAUUCAGCCUAAGAUAACCAAGGAGUUUGACGGU  
UGUCCACUCUAUGGAAAUCCUGAUGACGUUGCAUACUGCAAAGGUCUUCUGGAGCCGUACAA  
GGACAGCUGCCGCAACCCCAUCAACUUCUACUACACCAUCUCCUGCGCCUUCGCCCGCU  
GUAUGGGUGGAGACGAGCGAGCCUCACACGUGCUGCUUGACUACAGGGAGACGUGCGCUGC  
UCCCGAAACUAGAGGAACCUGCGUUUUGUCUGGACAUCUUUCUACGAUACAUUUGACAAAG  
CAAGAUACCAAUUCCAGGGUCCUGCAAGGAGAUUCUUAUGGCCGCGACUGUUUCUGGAAC  
ACUUGGGAUGUGAAGGUUUCACACAGGAAUGUUGACUCUUAACUGAAGUAGAGAAAGUACG  
AAUCAGGAAACAUCGACUGUAGUAGAACUCAUUGUUGAUGGAAAACAGAUUCUGGUUGGAG  
GAGAAGCCGUGUCCGUCCCGUACAGCUCUCAGAACACUCCAUCUACUGGCAAGAUGGUGAC  
AUACUGACUACAGCCAUCUACCUGAAGCUCUGGUGGUCAAGUUAACUUAAGCAACUGCU  
CGUCGUACAUAUUAGAGAUCCAUCGAUGGUAAGACUUGCGGUUUUGCGGUAACUACAACC  
AGGAUUUCAGUGAUGAUUCUUUUGAUGCUGAAGGAGCCUGUGAUCUGACCCCAACCCACCG  
GGAUGCACCGAAGAACAGAAACCUGAAGCUGAACGACUCUGCAAUAGUCUCUUCGCCGGUCA  
AAGUGAUCUUGAUCAGAAAUGUAACGUGUGCCACAAGCCUGACCGUGUCGAACGAUGCAUGU  
ACGAGUAUUGCCUGAGGGGACAACAGGGUUUCUGUGACCACGCAUGGGAGUUCAAGAAAGAA  
UGCUAACAUAAGCAUGGAGACACCCUAGAAGUACCAGAUUGAAUGCAAUAAAUGUUUCUCUUU  
UUUUAACAUGUCUCACAUAGAGUAUCUCCGAAUGCAGCUAUGUAAAAGA**GAACCAAAACU**UG  
AGUGCUCUGGAUAACUAUAUGGAAUGCUUUCUAA**GAAC**AGCUGAAGCUAAUCUAAUUUAAAUU  
UACAGCUUGAAGAGGUAGCUAGGUGUUUAAAGUUCUCCAGAUACUUUUACCUGAGUGAUG  
CUUCCCUUCCUAAGGCUGACCAAGACCUGUUGAUCUUAUAGAUUAAAAUAAAUGUCGCAU  
GUAAGGCUGAAGUCGCGUUUAUCAGAAUGCCUUGCCUUCUUAAGGUUCUUUUCCAUAUUGU  
CAAAGGUCCAGGCUCCAGUAGGAGAGAAAGAACUCCUCAUAGGAAUACUGAAGAAGUGGGAA  
GGAACCAAGCUGACACAGGCCUCACUGCAAUUUGAUUAGCCUGCUGAUCAGAGUCUCUUGGG  
CAUUUUUAUUUUUGCAUUCUGAUGUACCUAGGAGUUUUGUUAACAGAUGAUGUAUGUGAGU  
AUUUUACCCAUUUUAUGCAAUUAACCAAUCAAACCAAAAAAAGUGACCAUGAAGUCCUGUAUU  
UGUCUUUUUACUACAUGUAGGAACUCUCAUGUGAAUGAGUACUGUAGUAAUCCAUCUUAUGG  
GAGCCUUAUUUCAGAAUAUUUCAACUGGUGCAAUUGGAAAAGACUUUCUCUUUUCCUUUA  
AGCUAAAGACAAGAAUAUCAUGCUAUACAGGUGCAACUCAUCCCGUUAUUAAAACCAAUG  
UAGGUUAAGGCAUUCUACCCUUGAAAUAGCUGUGUCCCAACCUGUUGCCAUAUGAUUUUUUG  
GAAUUGGCUUUAGAAAUAUCCAAGUUGUCCUUGAAUUGUCUAACCAUGGACAUAACAGUUG  
UCUCCCUUCUACUGUGUAGAAUACUUGACUUAUUUUUCUCCAGAUACAGGGGGAUACCUG  
CCUGUUUUUCAAGUGUUUAUUUACUGCUGUUAUUUGAUUAGAAUGUAUUAAAUAAAAA

AACCGAUUUCUACAAGUUGCACUUAUUGAGUUCUAGAGAACGUACACUUUCAUGGUAUAG  
AGGAUUGCCAUA AAAACUUACGUCAAGUGAAUAAGCCAUAUUAUCAAAAAGGUAGAACA  
UACUUGCCAUUCUGUAAAGUUAUGGGCUGUACCUGCCCCCUUUGCAAUUUGGAAAGCAUGGU  
UUAGAAACUACAGGCAUUGUCAAGUGGCCGGGUCUUUUAUAAUUUGAAUAGGCAUAACACUG  
AUGUCCUCUGUGUUUCCAAAAACAUGGUUUAGAAACUACAAACAUAUUGACAUGGCCAGUCUU  
UUACAAGUUGAGUAGGCAUAAUACUAAAGAAAAAUACAAAGUUUUGUGGCCACUUAUUUUUUG  
CUAUGUUAGUCUGCAUAACUGUUUAUAAAUGUACCAUCUUUUCUAGAGUCCAGACAUAUUUAU  
UUUAUGGCUUUAAAAUUUCCUGCAUAGCUACAAUCCUGUGGUGUGUCACCAUAAAGGUGGA  
CCUGUGUGAAUGAGAAAAUUCAGUUUAUAAUUGUAAUAAAACCGCUUACUGG

## Supplementary References

- 1 Wang, X. *et al.* Structural basis of N(6)-adenosine methylation by the METTL3-METTL14 complex. *Nature* **534**, 575-578, doi:10.1038/nature18298 (2016).
- 2 Slaymaker, I. M. *et al.* High-Resolution Structure of Cas13b and Biochemical Characterization of RNA Targeting and Cleavage. *Cell Reports* **26**, 3741-3751.e3745, doi:10.1016/j.celrep.2019.02.094 (2019).
- 3 Liu, X.-M., Zhou, J., Mao, Y., Ji, Q. & Qian, S.-B. Programmable RNA N6-methyladenosine editing by CRISPR-Cas9 conjugates. *Nature Chemical Biology*, doi:10.1038/s41589-019-0327-1 (2019).